Acta Haematologica

Original Paper

Anemia in Heart Failure: Association of Hepcidin Levels to Iron Deficiency in Stable Outpatients

Weber C.S.a · Beck-da-Silva L.b · Goldraich L.A.b · Biolo A.b · Clausell N.b

Author affiliations

Divisions of aHematology and bCardiology, Hospital de Clínicas de Porto Alegre, Postgraduate Program for Clinical Sciences, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Keywords: AnemiaHeart failureHepcidinInflammationIron deficiency

Related Articles for ""
Acta Haematol 2013;129:55–61
https://doi.org/10.1159/000342110

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 20, 2011
Accepted: July 06, 2012
Published online: November 07, 2012
Issue release date: January 2013

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Abstract

Background: Anemia is a prevalent condition in heart failure with multiple potential causes. The complex interaction between iron stores, hepcidin, inflammation and anemia is poorly comprehended. We tested the hypothesis that, in stable heart failure patients with anemia, hepcidin is associated with iron deficiency status irrespective of inflammation. Methods and Results: Stable systolic heart failure outpatients with and without anemia underwent a complete iron panel, erythropoietin, hepcidin and tumor necrosis factor (TNF)-α assessment. Sixty outpatients were studied. Anemic patients (n = 38, mean hemoglobin 11.4 ± 1 g/dl) were older (69.6 ± 9.6 vs. 58 ± 10.8 years old, p < 0.01) compared with nonanemic patients (n = 22, mean hemoglobin 13.8 ± 1.1 g/dl). Iron deficiency was present in 42% of patients with anemia. TNF-α and hepcidin were 29 and 21% higher in patients with anemia, respectively, compared to nonanemic patients; however, no correlations were found between hepcidin and TNF-α levels. Hepcidin levels in the lower tertile (<31.7 ng/ml) were strongly associated with iron deficiency (OR 16.5, 95% CI 2.2–121.2; p < 0.01). Conclusion: In stable heart failure patients with anemia, hepcidin levels may be more importantly regulated by patients’ iron stores than by inflammation.

© 2012 S. Karger AG, Basel



Related Articles:

References

  1. Anand IS: Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008;52:501–511.
    External Resources
  2. Tang YD, Katz SD: Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454–2461.
    External Resources
  3. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J: Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005;91:907–913.
    External Resources
  4. Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008;51:569–576.
    External Resources
  5. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223–225.
    External Resources
  6. Yasaka Y, Yamabe H, Yokoyama M: Dependence of peak oxygen uptake on oxygen transport capacity in chronic heart failure: comparison of graded protocol and fixed protocol. Int J Cardiol 1997;59:149–156.
    External Resources
  7. Adlbrecht C, Kommata S, Hulsmann M, Szekeres T, Bieglmayer C, Strunk G, Karanikas G, Berger R, Mortl D, Kletter K, Maurer G, Lang IM, Pacher R: Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J 2008;29:2343–2350.
    External Resources
  8. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI: Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485–2489.
    External Resources
  9. Beck da Silva L, Rohde LE, Clausell N: Etiology and management of anemia in patients with heart failure: how much iron is missing? Congest Heart Fail 2008;14:25–30.
    External Resources
  10. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L: Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232–2237.
    External Resources
  11. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ: Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166–171.
    External Resources
  12. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS: Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926–1932.
    External Resources
  13. Ganz T: Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Educ Program 2006;2006:29–35, 507.
    External Resources
  14. Dallman PR: Iron Nutrition in Health and Disease. Eastleigh, John Libbey & Co, 1996.
  15. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.
    External Resources
  16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
    External Resources
  17. Grossman GB, Rohde LE, Clausell N: Evidence for increased peripheral production of tumor necrosis factor-alpha in advanced congestive heart failure. Am J Cardiol 2001;88:578–581.
    External Resources
  18. Koulaouzidis A, Saeed AA, Abdallah M, Said EM: Transferrin receptor level as surrogate peripheral blood marker of iron deficiency states. Scand J Gastroenterol 2009;44:126–127.
    External Resources
  19. Rohde LE, Beck da Silva L, Goldraich L, Grazziotin TC, Palombini DV, Polanczyk CA, Clausell N: Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can J Cardiol 2004;20:697–702.
    External Resources
  20. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM: Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226–229.
    External Resources
  21. Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Akahori H, Sakoda T, Ohyanagi M, Tomosugi N, Masuyama T: Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J 2010;74:301–306.
    External Resources
  22. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA: Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010;12:943–950.
    External Resources
  23. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T: Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009;296:H585–H593.
    External Resources
  24. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103–112.
    External Resources
  25. Maeder MT, Khammy O, dos Remedios C, Kaye DM: Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 2011;58:474–480.
    External Resources
  26. Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzoska K, Piotrowski W, Rywik TM, Danko B, Polkowska-Motrenko H, Rozanski JM, Kruszewski M: Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol 2012;159:47–52.
    External Resources
  27. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P: Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872–1880.
    External Resources
  28. Okonko DO, Anker SD: Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004;10:S5–S9.
    External Resources
  29. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, Chapman CM: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225–1227.
    External Resources
  30. Toblli JE, Lombrana A, Duarte P, Di Gennaro F: Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657–1665.
    External Resources
  31. Usmanov RI, Zueva EB, Silverberg DS, Shaked M: Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008;21:236–42.
    External Resources
  32. Gaber R, Kotb NA, Ghazy M, Nagy HM, Salama M, Elhendy A: Tissue doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography 2011, E-pub ahead of print.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 20, 2011
Accepted: July 06, 2012
Published online: November 07, 2012
Issue release date: January 2013

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2013, Vol.129, No. 1

January 2013

Article

Recommend This
TOP